Use of ANAR for the therapy of opium withdrawal syndrome

• Published in: Bulletin of experimental biology and medicine Vol. 135 Suppl 7; p. 181
• Main Authors: Gofman, A G, Krylov, E N, Kozhinova, T A, Nizhnichenko, T I, Khanykov, V V, Sheveleva, O S, Epstein, O I, Yashkina, I V
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 2003
• Subjects: Adult; Analgesics - immunology; Analgesics - therapeutic use; Antibodies - immunology; Antibodies - therapeutic use; Humans; Hypnotics and Sedatives - immunology; Hypnotics and Sedatives - therapeutic use; Morphine - immunology; Opioid-Related Disorders - drug therapy; Opium; Substance Withdrawal Syndrome - drug therapy; Treatment Outcome; Young Adult

We studied the efficiency of ANAR containing antibodies to morphine (dilutions C300 and C200) in the therapy of patients with the opium withdrawal syndrome. In patients with moderate to severe forms of the opium withdrawal syndrome therapeutic activity of ANAR was comparable to that of standard symp...